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Abstract Background Women with a history of spontaneous preterm birth (SPTB) are at a
significantly increased risk for recurrent preterm birth (PTB). To date, only one large U.S.
clinical trial comparing 17-OHPC (17-α-hydroxyprogesterone caproate or “17P”) to placebo
has been published, and this trial was stopped early due to a large treatment benefit.
Objective This study aimed to assess whether 17-OHPC decreases recurrent PTB and
neonatal morbidity in women with a prior SPTB in a singleton gestation.
Study Design This was a double-blind, placebo-controlled international trial involving
women with a previous singleton SPTB (clinicaltrials.gov: NCT 01004029). Women were
enrolled at 93 clinical centers (41 in the United States and 52 outside the United States)
between 160/7 to 206/7 weeks in a 2:1 ratio, to receive either weekly intramuscular (IM)
injections of 250mg of 17-OHPC or an inert oil placebo; treatment was continued until
delivery or 36 weeks. Co-primary outcomes were PTB<35 weeks and a neonatal
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In 2003, Meis and colleagues, on behalf of the Eunice
Kennedy Shriver National Institutes of Child Health and
Human Development (NICHD), Maternal-Fetal Medicine
Units (MFMU) Network, published the results of a random-
ized controlled trial (RCT) which demonstrated that 250mg
weekly intramuscular (IM) injection of 17-α-hydroxypro-
gesterone caproate (17-OHPC) could reduce the risk of
recurrent preterm birth (PTB) in women with a prior
spontaneous PTB (SPTB) by approximately 34% compared
with placebo (relative risk [RR]¼0.66 [95% confidence
interval (CI): 0.54–0.81]).1 This trial was conducted across
19 sites which were university-based academic medical
centers. Originally planned with a sample size of 500
women, it was stopped early by the Data Safety Monitoring
Committee (DSMC) based on prespecified rules, when it
was considered unethical to continue recruitment given the
robust evidence of efficacy with PTB<37 weeks. Although
underpowered to assess neonatal morbidities, the RR point
estimates for neonatal death, respiratory distress syndrome,
bronchopulmonary dysplasia, intraventricular hemorrhage,
and necrotizing dysplasia were all <1.0 and ranged from
0.25 to 0.63.
Also published in 2003, Fonesca and colleagues2 reported
the results of their RCT of vaginal progesterone to prevent
PTB. This trial, conducted in Brazil and involving 142 women
at high-risk for PTB, reported that vaginal progesterone
decreased PTB<37 and<34 weeks. The positive treatment
benefits from these two RCT’s prompted the American
College of Obstetricians and Gynecologists (ACOG) to state
“recent studies support the hypothesis that progesterone
supplementation reduces preterm birth in a select group of
women (i.e., those with a prior spontaneous birth at <37
weeks of gestation).”3 In 2008, ACOG and the Society for
Maternal Fetal Medicine (SMFM) coauthored a document
that stated, “progesterone supplementation for the preven-
tion of recurrent preterm birth should be offered to women
with a singleton pregnancy and prior SPTB.”4
In 2011, the U.S. Food and Drug Administration (FDA)
granted conditional approval of 17-OHPC for commercial use
in the United States under the Subpart-H accelerated approv-
al pathway.5 Accelerated approval under the Subpart-H
regulatory pathway is allowed for new drugs that are
intended to treat serious or life-threatening conditions and
provide meaningful benefit to patients over existing treat-
ments.6 In addition to accelerated approval, 17-OHPC was
granted Orphan Drug Designation, as its indicated popula-
tion affects less than 200,000 patients in the United States
annually. In an analysis of the potential impact of 17-OHPC
on PTB rates in the United States, based on 2002 natality data
Petrini et al estimated there were approximately 132,000
women per year who would be eligible for 17-OHPC thera-
py.7 In general, the FDA requires a newdrug to have data from
two adequate and well-controlled clinical trials as substan-
tial evidence of effectiveness. Although not planned or con-
ducted as a drug approval trial, the NICHD study was a key
aspect to provide evidence of 17-OHPC effectiveness; a
death, grade 3 or 4 intraventricular hemorrhage, respiratory distress syndrome,
bronchopulmonary dysplasia, necrotizing enterocolitis, or proven sepsis. A planned
sample size of 1,707 patients was estimated to provide 98% power to detect a 30%
reduction in PTB<35 weeks (30% to 21%) and 90% power to detect a 35% reduction in
neonatal composite index (17%–11%) using a two-sided type-I error of 5%. Finally, this
sample size would also provide 82.8% power to rule out a doubling in the risk of fetal/
early infant death assuming a 4% fetal/early infant death rate. Analysis was performed
according to the intention-to-treat principle.
Results Baseline characteristics between the 1,130 women who received 17-OHPC
and 578 women who received placebo were similar. Overall, 87% of enrolled women
were Caucasian, 12% had>1 prior SPTB, 7% smoked cigarettes, and 89% were married/
lived with partner. Prior to receiving study drug, 73% women had a transvaginal cervical
lengthmeasurement performed and<2% had cervical shortening<25mm. There were
no significant differences in the frequency of PTB<35 weeks (17-OHPC 11.0% vs.
placebo 11.5%; relative risk¼0.95 [95% confidence interval (CI): 0.71–1.26]) or
neonatal morbidity index (17-OHPC 5.6% vs. placebo 5.0%; relative risk¼1.12 [95%
CI: 0.68–1.61]). There were also no differences in frequency of fetal/early infant death
(17-OHPC 1.7% vs. placebo 1.9%; relative risk¼0.87 [95% CI: 0.4–1.81]. Maternal
outcomes were also similar. In the subgroup of women enrolled in the United States
(n¼391; 23% of all patients), although the rate of PTB<35 weeks was higher than the
overall study population, there were no statistically significant differences between
groups (15.6% vs. 17.6%; relative risk¼0.88 [95% CI: 0.55, 1.40].
Conclusion In this study population, 17-OHPC did not decrease recurrent PTB and
was not associated with increased fetal/early infant death.
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condition of FDA approval was that the sponsor had to
complete a confirmatory trial.
This confirmatory trial was designedwith the input of the
FDA to assess the efficacy of 17-OHPC based on both PTB and
neonatal morbidity and to assess the safety based on fetal/
early infant death. The FDA also required a long-term infant
follow-up study. As it was recognized that 17-OHPC had
largely become an acceptable standard of care in the United
States for this indication, FDA required that at least 10% of
study participants be enrolled from North American sites.
This study report describes the confirmatory trial, called the
PROLONG study (Progestin’s Role in Optimizing Neonatal
Gestation)8; the efficacy objective was to assess whether 17-
OHPC decreases recurrent PTB and neonatal morbidity in
womenwith a prior SPTB in a singleton gestation and a safety




The PROLONG study was a multicenter, randomized, con-
trolled, parallel group, double-blind trial at 93 total centers
across nine countries (see SupplementaryMaterial [available
in the online version] for all participating clinical sites).
Clinical sites were required to be associated with a hospital
which had access to level-3 or greater neonatal intensive care
unit (NICU). This trial was conducted in accordance with
Good Clinical Practices guidelines and the provisions of the
Declaration of Helsinki. Qualified representatives of the
Sponsor monitored the study according to a predetermined
monitoring plan to verify protocol adherence and accuracy
and completeness of data. The protocol was approved by the
institutional review board at each hospital before partici-
pants’ enrollment. The protocol was developed in consulta-
tion with the FDA and mirrored the study protocol from the
NICHD MFMU trial. The trial was registered at clinicaltrials.
gov (NCT01004029)9 along with an infant follow-up study
which is still ongoing (NCT01146990).10 The protocol and
other study materials are available in Supplementary Mate-
rial (available in the online version). Written informed
consent was obtained from all participants before randomi-
zation. As part of the consent process, participants were
informed in their native language of the results of the NICHD
MFMU study and after 2011 that 17-OHPC had been ap-
proved for use by the FDA.
Screening and Recruitment
Women18 years old, with a singleton pregnancywho had a
documented previous pregnancy complicated by a singleton
SPTB and who were 160/7 to 206/7 weeks in the current
pregnancy were eligible for the trial. SPTB was defined as
delivery from 200/7 to 366/7 weeks following spontaneous
preterm labor or preterm rupture of membranes (PROM).
Women were excluded for the following reasons: multifetal
gestation, known major fetal anomaly, heparin treatment
during the current pregnancy, current or planned cervical
cerclage, hypertension requiring medication, a seizure dis-
order, or use of progesterone treatment in any form (i.e.,
vaginal, oral, and IM) during current pregnancy. In 2013, the
study protocol was modified to allow for enrollment of
women if they received micronized progesterone (orally or
vaginally) provided it was stopped at least 4 weeks prior to
the first dose of study medication. An obstetric ultrasono-
graphic examinationwas required at 140/7 to 203/7 weeks for
gestational dating and evaluation for fetal anatomic
abnormalities.
Randomization and Treatment
After informed consent, women were administered a trial
injection of placebo and asked to return in 1 week at which
time eligibility was reassessed to determine if they could be
randomized. Womenwere randomly allocated 2:1 to receive
17-OHPC or placebo once per week from randomization
through 366/7 weeks or delivery, whichever occurred first.
Randomization was performed via an interactive voice re-
sponse system using a computer-generated schedule with a
block sequence of random blocks of size 3 and 6, stratified by
study site and gestational age at randomization (160/7–176/7
weeks and 180/7–206/7 weeks).
The 17-OHPC was supplied as a sterile solution containing
the active ingredient (hydroxyprogesterone caproate, 250mg/
mL), benzyl benzoate, castor oil, and benzyl alcohol. Placebo
was identical,minus theactive ingredient, andwasmatched in
color and appearance compared with 17-OHPC. Both the 17-
OHPC and placebo were identical to the formulations used in
the MFMU network trial. The study drug was given by the
study site personnel as a 1mL intramuscular injection in the
upper outer quadrant of the gluteus maximus. The women,
their caregivers, and research personnel were not informed of
the study-group assignment. Other than administration of the
study drug, the research protocol did not dictate any specific
treatment regimen and pregnancy management was at the
discretion of the treating clinician. Transvaginal ultrasound
cervical length measurement was performed following local
clinical care guidelines and was not prescribed by the study
protocol. Management of shortened cervix was at the discre-
tion of the patient’s attending physician.
Trial Outcomes
PROLONG had co-primary efficacy outcomes; PTB<35 weeks
(all deliveries occurring from randomization until 350/7 weeks
of gestation, including miscarriages or abortions occurring
from 160/7 through 196/7 weeks) and a composite neonatal
morbidity andmortality index. The composite index included
any of the following: neonatal death, grade-3 or-4 intraven-
tricular hemorrhage, respiratory distress syndrome, broncho-
pulmonary dysplasia, necrotizing enterocolitis, or proven
sepsis. Secondary outcomes were neonatal death, PTB<320/
7 weeks and PTB<370/7 weeks, as well as spontaneous and
medically indicated PTB<320/7, <350/7, and <370/7 weeks.
The primary safety outcome was fetal/early infant death
defined as any of the following: spontaneous abortion/mis-
carriage (delivery from 160/7–196/7 weeks of gestation),
stillbirth delivering after 200/7 weeks through term, or early
infant death. Early infant death was defined as death after
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birth until 28 days of life occurring in live-born neonates
delivered <240/7 weeks of gestation. The secondary safety
outcomes analyzed were the individual components of the
primary safety outcome as well injection reactions, maternal
complications, and other adverse events. Standardized def-
initions for neonatal and safety outcomes can be found in the
PROLONG protocol (see►Supplementary Material, available
in the online version). Neonates were followed through
28 days of life or discharged from the NICU, whichever
was later. All cases of miscarriage, stillbirth, and neonatal
death were reviewed blinded to study drug in a standardized
process and categorized by both local investigator and by an
MFM expert for causality related to study medication (defi-
nite, probable, possible, unlikely/remote, and definitely not).
Statistical Analysis
The study was designed to have adequate power for the
coprimary efficacy analyses and the primary safety analyses.
Baseline outcome rates (PTB, neonatal outcomes, and safety
measures) and treatment effects (17-OHPC vs. placebo)
utilized for sample size estimates were extrapolated from
the NICHD MFMU network trial. A total of 1,665 live-born
infants were required to detect a reduction of 35% in the rate
of the composite index (17%–11%) with a power of 90% and a
two-sided type-I error of 5%. Assuming 2.5% of pregnancies
would result in miscarriage or stillbirth, an additional 42
patients were planned to be enrolled for a total of 1,707
(1,138 active and 569 placebos). A total sample size of 1,707
patients provided 98% power to detect a reduction of ap-
proximately 30% in the rate of PTB<350/7weeks (from30% to
21%) using a two-sided type-I error of 5%. This sample size
assumed there would be adequate power (>92%) to detect
clinically significant reductions in the secondaryoutcomes of
PTB<320/7 and<370/7 weeks. Finally for the primary safety
outcome, assuming a 4% fetal/early infant death rate in both
treatment groups with a two-sided type-I error of 5%, a
sample size of 1,707 patients would provide 82.8% power to
rule-out a doubling in the risk of fetal/early infant death (i.e.,
the upper bound of the confidence interval [CI] for the RR of
17P compared with placebo will be 2.0).
Evaluation for statistical differences between the 17-
OHPC and placebo groups in the percentage of patients
who delivered <350/7 weeks gestation and the percentage of
neonates with the neonatal composite index were deter-
mined using Cochran–Mantel–Haenszel (CMH) tests strati-
fied by gestational age at randomization. Analyses were
performed according to the intention to treat principle.
Patients with missing delivery or neonatal composite index
data had the endpoint imputed, using a multiple imputation
analysis, assuming a monotone missing data pattern. A
logistic regression with treatment, gestational age at ran-
domization, the interaction of treatment and gestational
age at randomization, and the number of previous preterm
deliveries including miscarriages and abortions were used
for imputation. The combined CMH statistic from the
imputed datasets was determined using the Wilson–Hilf-
erty transformation. Since PTB<350/7 weeks and the neo-
natal composite index were coprimary outcomes, no
adjustment for multiplicity were planned.
For the primary safety outcome of fetal/early infant death
an adjusted RR (for gestational age at randomization) and a
95% CI for the RR was calculated using the CMH procedure. If
the upper bound of the CI was <2.0, it would be interpreted
that 17P-OHPC did not increase the risk of fetal/early infant
death.
Descriptive statistics were provided by treatment group
for baseline variables, primary, secondary, and additional
efficacy and safety outcomes. Adjusted (for gestational age at
randomization) RRs and 95% CIs for the RRs were calculated
based on the observed data (i.e., not using an imputation
procedure) using the CMH procedure. Prespecified subgroup
analyses for the primary outcome and exploratory sub
analyses for selected secondary outcomes included evaluat-
ing treatment effects by maternal race, location of recruit-
ment (the United States vs. the non–United States), and
gestational age of qualifying prior preterm birth. The statis-
tical analysis plan is provided (see ►Supplementary
Material, available in the online version).
An independent DSMC monitored the trial for safety and
met annually and reviewed safety and side-effect data. Given
the necessity to complete this study as part of FDA approval,
no interim analyses were performed for efficacy and there
were no futility parameters.
Role of the Funding Source
This study was designed and conducted by the Sponsor,
originally Hologic and KV Pharmaceutical, then Lumara
Health and subsequently AMAG Pharmaceuticals. During
the 9-year period that the trial was conducted, there were
two contract research organizations overseeing the study,
PRA International and ResearchPoint Global. Analyses were
performed by biostatistician (AFD) in conjunction with the
authors. Study authors had access to all study data and
independence regarding data analyses, interpretation of
findings, and manuscript preparations.
Results
Characteristics of the Participants
The first patient was randomized on November 12, 2009 and
the last study visit was October 8, 2018. After prescreening,
based on medical record and chart review, 1,877 women
were assessed more thoroughly for eligibility. Due to the
nature of chart screening and eligibility assessment, the
specific number of womenwhowere evaluated for potential
eligibility and/or declined participation was not tracked. A
total of 1,740 womenwere eligible, consented, and agreed to
the test injection (►Fig. 1). Of these, 1,708 remained eligible
for the study and returned for the randomization visit; 1,130
womenwere allocated to 17-OHPC and 578were allocated to
placebo (►Fig. 1). Therewere 391 women randomized in the
United States and 1,317 women randomized non-United
States (see►SupplementaryMaterial [available in the online
version] for recruitment by site).
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There were no differences in demographic or clinical
characteristics between study groups (►Table 1). Most of
the participants were white (87%), few had >1 prior SPTB
(13%), 89% were married, and 8% smoked. There were no
differences in number of study medication injections be-
tween those receiving 17-OHPC (median¼18, range: 1–22)
or placebo (median, 18, range: 1–22) or the rate of full
compliance (91.4 vs. 92.4%).
Primary Outcomes and Other Perinatal Outcomes
No difference between treatment groups was found for
either coprimary efficacy outcome; PTB<350/7 weeks (17-
OHPC 11.0% vs. placebo 11.5%; RR¼0.95 [95% CI: 0.71–1.26];
p¼0.72) and neonatal composite index (17-OHPC 5.6% vs.
placebo 5.0%; RR¼1.12 [95% CI: 0.70–1.66]; p¼0.73). A
review of the individual components of the neonatal com-
posite index indicates no differences between the treatment
groups for any of the components assessed. The frequency of
respiratory distress syndrome drove the composite out-
comes for both groups.
Similarly, the rate of PTB<37 and<32 weeks were not
different (►Table 2). Maternal outcomes including need for
cerclage placement, tocolysis, antenatal corticosteroid ther-
apy, gestational diabetes, preeclampsia, chorioamnionitis,
and abruption were also not different (►Table 3). In the
PROLONG, the rates of PTB were higher in the United States
patients compared to the non-U.S. patients (data presented
in ►Supplementary Material, available in the online ver-
sion). Outside the United States, the rates of PTB in the
regionswith thehighest enrollments (i.e., Russia andUkraine
that accounted for 60% of all patients enrolled) were among
the lowest observed.
The fetal/early infant death rates were lower than
expected and not different between treatment groups (17-
OHPC 1.7 vs. placebo 1.9%; RR¼0.87 [95% CI: 0.4–1.81]).
Patients receiving 17-OHPC had a lower risk of miscarriage
(17 OHPC 0.5% vs. 1.6%; RR¼0.28 [95% CI: 0.08–0.94]) and
there was no statistically significant difference in the fre-
quency of stillbirth (17-OHPC 1.1% vs placebo 0.5%; RR 2.07
[95% CI 0.59–7.29]) (►Table 4). Assessment of causality of the
relationship of study drug in the cases of miscarriage,
stillbirth, and neonatal outcomes is described in
►Supplementary Material (available in the online version).
A total of 1,253 women had transvaginal ultrasound
cervical length performed prior to receiving study medica-
tion and 18 (1.4%) had measurement <25mm. Of them,
22.2% (4/18) in the 17-OHPC group and 44.4% (4/9) in the
placebo group had PTB<35 weeks. Of women with cervical
length >25mm, 9.6% (78/810) in the 17-OHPC group and
9.5% (39/410) in the placebo group had PTB <35 weeks.
Fig. 1 Patient eligibility, randomization, and assessment. HPC, hydroxyprogesterone caproate; PROLONG, Progestin’s Role in Optimizing
Neonatal Gestation; PTB, preterm birth, sPTB, spontaneous PTB.
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Discussion
The PROLONG trial was conducted in consultation with the
FDA (as part of FDA approval for the use of 17-OHPC) for the
purpose of serving as a confirmatory study following the
MFMU trial. However, unlike the robust positive findings of
the NICHD MFMU trial, the PROLONG study had a much
lower event rate of PTB (almost 50% lower) and did not
confirm treatment efficacy. Given the much lower than
expected event rates, PROLONG, despite its large sample
size, was underpowered to assess treatment efficacy related
to PTB endpoints and neonatal outcomes. Event rates for
pregnancy loss (fetal/early infant death) were lower than
expected and not different between groups. Although not
statistically significant, therewas an increase in the frequen-
cy of stillbirth in the 17-OHPC group. A detailed clinical
review of these cases noted factors unassociated with 17-
OHPC as the suspected cause in the majority of cases. There
were also no differences in the rates of gestational diabetes.
Despite having the same eligibility criteria and study pro-
tocol, the MFMU trial and PROLONG ended up having very
dissimilar patient populations which may explain themarked
difference in PTB event rates. In theMFMU trial, womenwere
recruited from United States academic medical centers and
had a high-baseline risk for PTB.1 In the NICHD trial, the
women receiving placebo had PTB<37, PTB<35, and PTB
<32 weeks of 54.9%, 30.7%, and 19.6%, respectively, while in
PROLONG, the rates were 21.9%, 11.5%, and 5.2%, respectively.
In PROLONG, most women were recruited from outside the
United States (75%). In Russia and Ukraine, where >60%
patients were enrolled, PTB<37 weeks occurred in 17.2%
and 21.1%, respectfully. Differences in race and socioeconomic
status betweenwomen in the NICHD trial and PROLONG non-
United States are clear, but there may also be another expla-
nation for the lower PTB event rates seen in PROLONG. When
PROLONG started recruitment in 2009,many physicians in the
United States were already prescribing 17-OHPC (or vaginal
progesterone) as routine care. Their interest and ability to
participate in a placebo-controlled trial was therefore limited.
Few, if any, United Statesmajormedical centersparticipated in
PROLONG because they had access to 17-OHPC or a compara-
ble treatment.Most siteswhochose toparticipate inPROLONG
did not have access to 17-OHPC for their patients, and there-
fore a two-thirds chance of receiving 17-OHPCwas better than
no chance. Over time, and especially with the FDA approval of
17-OHPC in 2011, it is possible thanwomenwith a higher risk





Maternal age (y) 30.0 5.2 29.95.2
Race
Black 73 (6.5) 41 (7.1)
Caucasian 1,004 (88.8) 504 (87.2)
Asian 23 (2.0) 22 (3.8)
Other 30 (2.7) 11 (1.9)
Hispanic or Latino ethnicity 101 (8.9) 54 (9.3)
No. of prior spontaneous PTB> 1 148 (13.1) 70 (12.1)
Prior elective abortion 281 (24.9) 142 (24.6)
Prior indicated PTB 19 (1.7) 13 (2.3)
Gestational age at qualifying prior SPTB (wk) 32 (28–35) 33 (29–35)
Prepregnancy BMI (kg/m2) 23 (21–27) 23 (21–27)
Marital status
Married/living with a partner 1,013 (89.6) 522 (90.3)
Never married 86 (7.6) 40 (6.9)
Divorced/widowed/separated 31 (2.7) 16 (2.8)
Years of education 13 (11–15) 13 (11–15)
Smoked during current pregnancy 92 (8.1) 41 (7.1)
Drank alcohol during current pregnancy 24 (2.1) 18 (3.1)
Used any “street drugs” during current pregnancy 16 (1.4) 8 (1.4)
Transvaginal cervical length <25 mm, n/N1a (%) 10/833 (1.2) 8/420 (1.9)
Prior vaginal progesterone therapy in pregnancy 16 (1.4) 10 (1.7)
Abbreviations: BMI, body mass index; OHPC, α-hydroxyprogesterone caproate; PTB, preterm birth; SPTB, spontaneous preterm birth.
Note: n is number of patients in the Intent to Treat population. Data expressed as n (%), median (inter-quartile range), or mean ( standard of
deviation).
aN1¼ number of patients with cervical length measurement performed prior to first dose of study drug; measured prior to the first dose of study drug.
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for recurrent PTB did not get enrolled in PROLONG but were
rather steered to open label therapy, to avoid the chance of
receiving a placebo. With these combinations of events, PRO-
LONG enrolled a lower risk profile of women, both in the
United States and outside the United States. The lower rate of
prior SPTB>1 and the very low rate of shortened cervix (<2%)
are indicators that womenwithmore severe obstetrical histo-
ries or conditionsmay have been (consciously or unconscious-
ly) steered away fromparticipation. Since PTB is not a singular
disease, but a syndrome with multiple pathways and etiolo-
gies,11,12 it is not unexpected that the disease severity, as
measured by the rate of recurrent PTB, has awide range. As an
example, in the PROLONG United States study population
(n¼391), PTB<37 weeks occurred in 28.8% of those who
received placebo. This is substantially greater than those
outside the United States, but stillmuch lower than theNICHD
trial. Another factor is that not allwomenmaybe “responders”
to17-OHPCas theremaybepharmacogenomicvariations (e.g.,
in the NICHD trial 36.3% of women treatedwith 17-OHPC had
PTB<37 weeks)13,14
Limitations and Strengths
One of the limitations of PROLONG is that the majority of
women were enrolled outside the United States and their
characteristics were quite different, which leads to uncer-
tainty on the applicability to a higher risk United States
population. The second major limitation is the fact that the
study was underpowered given the much lower than
expected event rates. The sample size estimates were based
on the NICHD trial which had very high event rates for both
PTB and neonatal morbidity. Assuming the same estimates
for sample size calculation, given the observed event rates,
PROLONG would have required 3,600 women to have 90%
power for PTB<35 weeks and 6,000women for the neonatal
composite outcome. Another limitation is the paucity of
women in PROLONG who had a short cervix. In the trial,
there were only 2% who had a short cervix, which is lower
than expected in a population of women with a prior
SPTB.15–17 The number of women in this subgroup does
not provide an adequate sample to assess treatment effect.






Number assessed for outcome, N1 1,113 574 0.95 (0.71–1.26)
PTB<350/7 wka 122 (11.0) 66 (11.5)
Spontaneous 93 (8.4) 51 (8.9) 0.93 (0.67–1.30)
Indicated 28 (2.5) 14 (2.4) 1.03 (0.55–1.93)
Number assessed for outcome, N1 1,112 572
PTB<370/7 wk 257 (23.1) 125 (21.9) 1.06 (0.88–1.28)
Spontaneous 209 (18.8) 98 (17.1) 1.10 (0.88–1.36)
Indicated 46 (4.1) 26 (4.5) 0.91 (0.57–1.46)
Number assessed for outcome, N1 1,116 574 0.92 (0.60–1.42)
PTB<320/7 wk 54 (4.8) 30 (5.2)
Spontaneous 38 (3.4) 22 (3.8) 0.88 (0.52–1.48)
Indicated 15 (1.3) 7 (1.2) 1.11 (0.46–2.63)
Cerclage 6 (0.5) 7 (1.2) 0.44 (0.15–1.32)
Preterm laborb 187(16.5) 84 (14.5) 1.14 (0.90–1.44)
Tocolysis 134 (11.9) 63 (10.9) 1.09 (0.82–1.44)
Antenatal corticosteroid therapy 105 (9.3) 61(10.6) 0.88 (0.65–1.20)
Maternal GDM 35 (3.1) 21 (3.6) 0.91 (0.54–1.54)
Preeclampsia 47 (4.2) 30 (5.2) 0.86 (0.51–1.46)
Chorioamnionitis 9 (0.8) 2 (0.3) 2.24 (0.48–10.41)
Abruption 16 (1.4) 4 (0.7) 2.04 (0.69–6.06)
Cesarean delivery 292 (25.8) 140 (24.2) 1.07 (0.90–1.27)
Abbreviations: CI, confidence interval; GDM, gestational diabetes mellitus; OHPC, α-hydroxyprogesterone caproate; PTB, preterm birth; RR, relative
risk.
Note: n¼ number of subjects in the intent toTreat population. N1¼ number of subjects with non-missing delivery data or with missing delivery data
who were known to be pregnant at the specified gestational age. Relative risk (RR) and confidence interval (CI) adjusted for gestational age at
randomization stratum and based on observed data (no imputation for missing data). Data expressed as n (%).Type of delivery (spontaneous and
indicated) is not available for women with missing delivery data.
ap-Value¼ 0.72 and is from the Cochran–Mantel–Haenszel test based on the sample sizes within each gestational age at randomization stratum.
Missing outcome data were imputed using a multiple imputation analysis.
bNot including episode of delivery event.
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Strengths of the PROLONG trial include its placebo-con-
trolled design, large sample size, low lost to follow-up rate and
planned infant follow-up study (on-going). Another strength is
that the study protocol mirrored the MFMU trial which has
allowed for direct comparisons with that trial. There was a
planned prespecified subgroup analysis to assess treatment
effects for the U.S. versus non-U.S. subgroups. In the U.S.-only
subgroup (n¼391) which had a higher baseline PTB rate
compared with the non-U.S. (i.e., PTB<37 weeks in U.S.-
only placebo group 28.2 vs. 20% in non-U.S. placebo group),
there were nonsignificant trends for treatment efficacy with
PTB<32 weeks (point estimate RR¼0.58) and<35 weeks
(RR¼0.88) but not <37 weeks (RR¼1.16). There was also a
nonsignificant trend for the neonatal composite (RR¼0.81).
These analyses should be considered exploratory and hypoth-
esis generating only. Finally, PROLONG included an on-going
follow-up study to determine whether there is a difference in
development status between children, aged 23 to 25 months
corrected gestational age, whose mothers received 17-OHPC
or placebo (clinicaltrial.gov: NCT01146990).






Composite neonatal morbidity and mortality indexa 61 (5.6) 28 (5.0) 1.12 (0.72–1.72)
Neonatal death 6 (0.5) 3 (0.5) 0.98 (0.24–3.91)
Bronchopulmonary dysplasia 6 (0.5) 1 (0.2) 3.02 (0.38–24.1)
Respiratory distress syndrome 54 (4.9) 26 (4.7) 1.06 (0.67–1.68)
Necrotizing enterocolitis 2 (0.2) 2 (0.4) 0.5 (0.07–3.40)
IVH, grade 3 or 4 2 (0.2) 1 (0.2) 0.99 (0.09–10.52)
Proven sepsis 5 (0.5) 3 (0.5) 0.84 (0.20–3.56)
NICU admission 137 (12.5) 58 (10.4) 1.21 (0.90–1.62)
Birth weight (g) 3,076.6 630.0 3,080.1609.2 NA
TTN 37 (3.4) 11 (2.0) 1.72 (0.89–3.33)
Number of neonates on ventilator support/receiving
supplemental oxygen
130 (11.9) 54 (9.7) 1.23 (0.91–1.67)
PDA 4 (0.4) 4 (0.7) 0.53 (0.14–2.06)
ROP 5 (0.5) 7 (1.3) 0.37 (0.12–1.16)
Neonatal LOS (for those admitted to the NICU) (d) 18.6 20.4 23.3 24.5 NA
Abbreviations: CI, confidence interval; IVH, intraventricular hemorrhage; LOS, length of stay; NA, not applicable; NICU, neonatal intensive care unit;
OHPC, α-hydroxyprogesterone caproate; PDA, patent ductus arteriosus; ROP, retinopathy of prematurity; RR, relative risk; TTN, transient tachypnea
of the newborn.
Note: Data expressed as n (%), median (interquartile range), or mean ( standard of deviation). n¼ number of neonates in the live-born neonatal
population. RR and CI are adjusted for gestational age at randomization stratum.
ap-Value¼ 0.62 and is from the Cochran–Mantel–Haenszel test based on the sample sizes within each gestational age at randomization stratum.






Fetal/early infant deathb 19/1128 (1.7) 11/578 (1.9) 0.87 (0.4–1.81)
Miscarriagec 4/866 (0.5) 7/448 (1.3) 0.28 (0.08–0.94)
Stillbirthd 12/1124 (1.1) 3/571 (0.5) 2.07 (0.59–7.29)
Early infant deathe 3/1112 (0.3) 1/568 (0.2) 1.48 (0.14–15.24)
Abbreviations: CI, confidence interval; OHPC, α-hydroxyprogesterone caproate; RR, relative risk.
aRelative risk is from the CMH test adjusted for gestational age at randomization stratum.
bDenominator is number of patients who received study drug. Fetal/early infant death is defined as a miscarriage, stillbirth, or neonatal death
through 28 days of life occurring in a live-born neonate at < 24 weeks of gestation.
cDenominator is number of patients who received study drug andwere randomized 200/7 weeks of GA.Miscarriage is defined as spontaneous delivery
from 160/7 to 196/7 weeks of gestation.
dDenominator is number of patients who received study drug and were pregnant beyond 200/7 weeks of GA. Stillbirth is defined as antepartum or
intrapartum death from 200/7 weeks of gestation through term.
eDenominator is number of patients who received study drug and did not have amiscarriage or stillbirth. Patients with missing data are assumed not
to have the specified outcome.
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Conclusion
In conclusion, current clinical guidelines in the United States
recommend the use of 17-OHPC inwomenwith prior SPTB.18
How best to adjudicate the findings of the PROLONG trial,
given it was underpowered and inconclusive regarding as-
sessment of treatment efficacy, will be challenging for clini-
cians, patients, and policy makers. Combining data in
systematic reviews and/or meta-analyses19,20 to attempt
to differentiate a population with the most optimal bene-
fit/risk ratio will be important. The absence of other evi-
dence-based interventions to offer this orphan population
(womenwith prior SPTB) combinedwith the reality that 17-
OHPC has been widely used for over 15 years adds to the
complexity. Finally, the feasibility of conducting another
placebo controlled RCT seems improbable, especially in the
United States.
Condensation
Inwomenwith a prior spontaneous preterm birth, weekly
17-OHPC compared with placebo did not reduce recur-
rent preterm birth or decrease neonatal morbidity.
Clinical Trial Registration
Date of registration: October 27, 2009.
Date of initial participant enrollment: November 12,
2009.
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